Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 61 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diabetes Mellitus Progression Clear all
Completed No phase listed Observational

Evaluation of Progression of Diabetic Retinopathy With Rapid Correction of Hyperglycemia

NCT02326259
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Initiation of treatment of diabetes
Other
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Jul 22, 2026, 6:55 PM EDT
Completed No phase listed Observational

Eliminating Hepatitis C Virus

NCT03401697
View directory record Official record
Conditions
Hepatitis C, HIV, Type2 Diabetes
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
52 participants
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes

NCT00947427
View directory record Official record
Conditions
Type 1 Diabetes, Preservation of Insulin Secretion, Newly Diagnosed Type 1 Diabetes, Canakinumab in Type 1 Diabetes
Interventions
canakinumab (anti IL-1beta), Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Years to 45 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
San Francisco, California • Stanford, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Jul 22, 2026, 6:55 PM EDT
Terminated Phase 4 Interventional

Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

NCT01591902
View directory record Official record
Conditions
Diabetic Retinopathy, HIV
Interventions
Tesamorelin, Placebo-Control
Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
24
States / cities
Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Jul 22, 2026, 6:55 PM EDT
Terminated No phase listed Observational

Rate of Change of HbA1c (dx/dt) May Predict Progression to Type 2 DM

NCT01315808
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Not listed
Lead sponsor
Wyckoff Heights Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Jul 22, 2026, 6:55 PM EDT
Withdrawn Phase 2 Interventional

Effect of GABA Supplementation in the Progression of Type 1 Diabetes in Children

NCT01561508
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
gamma-amino-butyric acid, Xylitol
Drug · Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
8 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 23, 2012 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus

NCT00505375
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
CTLA-4 Ig, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Years to 45 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 4 Interventional

Semaglutide Treatment On Coronary Progression

NCT03985384
View directory record Official record
Conditions
Type 2 Diabetes, Coronary Artery Disease
Interventions
Semaglutide 2 MG/1.5 ML Subcutaneous Solution, Placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
40 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Not applicable Interventional

Simultaneous Risk Factor Control Using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD)

NCT01829256
View directory record Official record
Conditions
Diabetes, Hypertension, Diabetic Kidney Disease
Interventions
Pharmacist telehealth intervention
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Jul 22, 2026, 6:55 PM EDT
Not yet recruiting Phase 3 Interventional

PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study

NCT07670650
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
SAB-142, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
5 Years to 40 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 22, 2026, 6:55 PM EDT
Recruiting Phase 4 Interventional

Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

NCT05708859
View directory record Official record
Conditions
Type II Diabetes, Atherosclerosis
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Matthew J. Budoff
Other
Eligibility
40 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Stop Atherosclerosis in Native Diabetics Study

NCT00147251
View directory record Official record
Conditions
Cardiovascular Disease, Hypertension, Hyperlipidemia, Diabetes, Carotid Atherosclerosis
Interventions
FDA approved drugs to treat blood pressure and cholesterol
Drug
Lead sponsor
Cynthia West
Other
Eligibility
40 Years and older
Enrollment
548 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
4
States / cities
Chinle, Arizona • Phoenix, Arizona • Lawton, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus

NCT00225277
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone, Glimepiride
Drug
Lead sponsor
Takeda
Industry
Eligibility
35 Years to 85 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Jul 22, 2026, 6:55 PM EDT
Completed No phase listed Observational

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)

NCT04477707
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Finerenone (BAY94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Not listed
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Chula Vista, California • El Centro, California • Fort Lauderdale, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Jul 22, 2026, 6:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Progression and Etiology of Cortical Porosity in Diabetic Bone Disease

NCT04208230
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
XtremeCT
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jul 22, 2026, 6:55 PM EDT
Not yet recruiting Not applicable Interventional

Artificial Intelligence-based Methods to Predict Disease Progression in Youth With Type 2 Diabetes

NCT07116902
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
phone application, Standard of Care (SOC)
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
10 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Oakland, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 2 Interventional

Prevention of Diabetes Progression Trial (PDPT)

NCT00198146
View directory record Official record
Conditions
Newly Diagnosed With Type 1 Diabetes
Interventions
Zenapax
Drug
Lead sponsor
Indiana University
Other
Eligibility
2 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Jul 22, 2026, 6:55 PM EDT
Terminated Not applicable Interventional Results available

Debritom - Micro Water Jet Technology and Wound Healing

NCT04240574
View directory record Official record
Conditions
Diabetic Foot Ulcer, Non-healing Wound, Non-Healing Ulcer of Skin, Venous Leg Ulcer, Venous Ulcer
Interventions
Debritom
Device
Lead sponsor
Stephanie Wu
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 26, 2023 · Synced Jul 22, 2026, 6:55 PM EDT
Withdrawn No phase listed Observational

Study to Evaluate Bacterial Activity That Drives the Progression of Clinical Infection

NCT03854695
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes

NCT00116831
View directory record Official record
Conditions
Atherosclerosis
Interventions
Glipizide, rosiglitazone maleate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 80 Years
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Jul 22, 2026, 6:55 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Imaging of Type 1 Diabetes Progression

NCT01521520
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ferumoxytol
Drug
Lead sponsor
Jason Gaglia
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Jul 22, 2026, 6:55 PM EDT
Not yet recruiting Phase 2 Interventional

Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG

NCT07216391
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Antithymocyte Globulin (ATG), Teplizumab
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
4 Years to 34 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

Rituximab in New Onset Type 1 Diabetes

NCT00279305
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Anti-CD20 (rituximab), Placebo Comparator
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

NCT03819153
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
3,533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
117
States / cities
Tuscumbia, Alabama • Chula Vista, California • Concord, California + 95 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Jul 22, 2026, 6:55 PM EDT